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Alzheimer disease (AD) is an age-related progressive neurodegenerative disorder. This devastating disease is characterized by the
presence of senile plaques (SP), neurofibrillary tangles (NFTs), and loss of synapses. Amyloid beta-peptide 1–42 (Aβ(1–42)) is
the main component of SP and is pivotal to AD pathogenesis. Brain of subjects with AD and arguably its earliest manifestation,
mild cognitive impairment (MCI), demonstrate increased levels of oxidative stress markers. Our laboratory combined these two
aspects of AD and MCI and proposed the Aβ(1–42)-associated free radical oxidative stress hypothesis to explain oxidative stress
under which the MCI and AD brain exist and the loss of synapses in both disorders. A large number of in vitro and in vivo studies
showed that Aβ causes protein oxidation, lipid peroxidation, reactive oxygen species formation, and cell death in neuronal and
synaptosomal systems. Methionine located at residue 35 of Aβ(1–42) is an important contributor to the oxidative stress associated
with this neurotoxic peptide. In this paper, we summarize studies involving Met-35 of Aβ(1–42). Understanding the role of the
single methionine residue of Aβ(1–42) may help in understanding underlying disease mechanisms in AD and MCI.
1. Introduction
Alzheimer disease (AD) is an age-related progressive neu-
rodegenerative disease. This devastating disease is character-
ized by the presence of senile plaques (SP), neurofibrillary
tangles (NFTs), and loss of synapses [1]. Although AD has
been known for over 100 years, the exact mechanism(s) of
AD progression or pathogenesis largely remain unknown.
Mutations of presenilin-1 (PS-1), presenilin-2 (PS-2), and
APP genes cause familial AD (FAD). In addition, other genes,
such as apolipoprotein E allele 4 (APOE 4), clusterin (CLU,
also called apolipoprotein J (APOJ)), phosphatidylinositol-
binding clathrin assembly protein (PICALM), endothelial
nitric oxide synthase-3, and alpha-2-macroglobulin, have been
suggested as risk factors for AD [2–5]. Studies showed that
injection of Aβ cores in rat brain leads to AD-like pathology
[6].
2. Oxidative Stress in AD andMild Cognitive
Impairment Brain
Brain of subjects with AD showed increased markers of
oxidative stress [7–10]. A number of hypotheses were
proposed to explain ADpathogenesis among which oxidative
stress hypothesis is well supported by numerous in vitro
and in vivo studies [11–15]. Oxidative stress is defined
as an imbalance between the amount of reactive oxygen
species (ROS)/reactive nitrogen species (RNS) and the
antioxidant defense system present (Figure 1). Increased
levels of ROS/RNS lead to increased damage of biomolecules,
such as proteins, lipids, carbohydrates, and nucleic acid.
Studies of postmortem tissue showed that AD brain is under
extensive oxidative stress, as supported by the elevated levels
of biomarkers of protein oxidation, lipid peroxidation, DNA,
and RNA oxidation, and advanced glycation end products
2 Journal of Amino Acids
oxidation/nitration
Neuronal death
Oxidants
(ROS/RNS) Oxidants
(ROS/RNS)
Antioxidants
Protein
Lipid peroxidation
Aβ
Normal neuronal function
Antioxidants
Figure 1: Amyloid beta (Aβ) peptide induces oxidative stress and neuronal loss.
[10, 16–25]. Further, increased oxidative stress has also been
found in MCI [11, 20, 26–30]. The increased markers of
oxidative stress in AD and MCI have been shown to be
associated with amyloid β-peptide (Aβ), a 40 to 42 amino
acid residue neurotoxic peptide, that is derived from the
proteolytic cleavage of amyloid precursor protein (APP), by
the action of beta- and gamma-secretase [31]. Aβ(1–42) has
been shown to aggregate more quickly than Aβ(1–40) and
is proposed to play a central role in AD pathogenesis. The
evidence of involvement of Aβ(1–42) in AD pathogenesis
is largely derived from the observation that FAD cases have
increased Aβ load and increased oxidative stress. Additional
evidence supporting a role of Aβ(1–42) is provided by
Down syndrome, characterized by a trisomy of chromosome
21. The gene for APP also is present on chromosome 21,
and in Down syndrome individuals, the increase dosage of
APP might be responsible for the observation of AD-like
pathology in these individuals, if they live long enough. DS
brain also has elevated oxidative stress [32].
3. Oxidative Stress and Aβ(1–42)
Consistent with the role of Aβ in oxidative stress induction
and consequently in AD pathogenesis, our laboratory and
others showed that Aβ-induced oxidative stress markers can
be alleviated by free radical scavengers such as Vitamin
E, melatonin, estradiol, EUK-34, and so forth [33–37]. As
discussed further below, our laboratory proposed a model
for pathogenesis of AD based on the central role of Aβ(1–42)
as a mediator of free-radical-induced oxidative stress in AD
brain [23]. In this model, Aβ(1–42) as small oligomers can
insert into the lipid bilayer and initiate lipid peroxidation,
and, consequently, oxidative damage to proteins and other
biomolecules [23]. A sequelae of this model is the influx of
Ca2+ into the neuron, resulting in loss of intracellular Ca2+
homeostasis, mitochondrial dysfunction, and ultimately
synapse loss and cell death.
Aβ exists in different aggregation states, among which
oligomeric Aβ is considered as the highly toxic form [38, 39].
Oligomeric Aβ also has been reported to be localized in
mitochondria [40, 41], principal foci for ATP generation
and a good source of free radicals. In vitro studies showed
that incubation of 9–11-day-old primary hippocampal neu-
ronal cultures with Aβ(1–42) leads to increased oxidative
stress markers and neurotoxicity [14, 42]. Consistent with
oxidative stress associated with this neurotoxic peptide,
the addition of vitamin E, a chain-breaking antioxidant,
significantly modulates the oxidative stress and neurotoxic
effects of Aβ(1–42) [33, 42, 43], suggesting that the Aβ(1–
42)-mediated toxicity is mediated via its ability to lead to
induce oxidative stress. Others showed that depletion of
vitamin E increases Aβ accumulation by decreasing clearance
from brain and blood in a mouse model of AD [44], and we
recently showed that the major efflux protein for Aβ(1–42)
from brain to blood, LRP-1, was oxidatively modified in AD
brain [25]. Studies conducted in our laboratory using Aβ(1–
42), Aβ(1–40), Aβ(17–42), and Aβ(25–35) showed that Met-
35 of these peptides is critical for Aβ-induced toxicity and
oxidative stress [14, 33, 45, 46]. Many researchers have
used Aβ(25–35), which mimics several of the oxidative and
neurotoxic properties of full-length Aβ(1–42). The shorter
peptide is reported to be more toxic than the regular Aβ(1–
42) which could be due to the presence of the methionine
residue at the peptide C-terminus. Several studies were
conducted to explore the role of C-terminal Met in Aβ(25–
35). Further, when the Met C-terminal carboxylic acid
functionality of Aβ(25–35) was substituted by an amide
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(-CONH2), the peptide no longer induced any oxidative
stress or neurotoxicity, suggesting that the initial attack
on the sulfur is important for Aβ-induced oxidative stress
and neurotoxicity. In addition, truncation of Aβ(25–35) to
Aβ(25–34), diminished oxidative stress and neurotoxicity
associated with Aβ(25–35) peptide [47]. However, is should
be emphasized that (a) Aβ(25–35) is not found in AD brain,
and (b) because the Met is located at the C-terminus in
this shorter peptide, while Met is located in a intrachain
position of AD-relevant Aβ(1–42), the mechanisms of Met-
centered radical cation formation (see below) in the two
peptides are completely different. Hence, we recommend
that Aβ(25–35) not be used for studies designed to gain
insights intomechanisms for Aβ(1–42). Although this review
concentrates on Met-35 of Aβ(1–42), other sources of ROS
and RNS likely contribute to the oxidative stress observed
in AD brain. For example, mitochondrial dysfunction, redox
metal reactivity, and so forth, could play an important role in
oxidative stress in AD.
4. Role ofMethionine-35 of Aβ(1–42) in
Oxidative Stress
Our laboratory was the first to propose that Aβ(1–42)
mediates its toxicity via the single methionine residue of the
peptide [46]. As shown in Figure 2, Aβ has Met present at
the 35th residue in the peptide. Met is an easily oxidizable
amino acid and can undergo 2-electron oxidation to form
methionine sulfoxide [48, 49]. Oxidation of Met has been
shown to occur in a wide variety of proteins and has been
shown to decrease or hinder biological activity [50, 51]. The
oxidation of Met to the sulfoxide could serve two purposes
biologically: first, as regulatory function, and secondly, in
cellular defense [52]. The notion that Met oxidation to the
sufoxide possibly serves an antioxidant role comes from
the fact that cell has an enzyme, methionine sulfoxide
reductase (MSR), that catalyzes the conversion of Met-
sulfoxide (MetSOx) to Met [53–55]. In AD, MSR activity
is diminished compared to control brain [56]. Further, the
MetSOx can be further oxidized to form a corresponding
sulfone, but this process requires a stronger oxidant; hence,
this conversion is not easily accomplished in vivo and is not
an easily reversible process.
The mechanism of free radical oxidation of sulfur in
Met-containing Aβ peptides has been extensively studied. In
AD brain, a significant fraction of SP-resident Aβ peptide
has Met in the form of MetSOx [57]. As noted, previous
investigations showed that MSR activity is reduced in AD
brain, which may lead to increase oxidation of Met [56].
In addition to 2-electron oxidation, the sulfur atom of
Met of Aβ(1–42) can undergo a one-electron oxidation
leading to the formation of a sulfuranyl radical cation
(S+·) or hydroxysulfuramyl radical cation [58]. Further, it
appears that H-atom abstraction, likely from the adjacent
methyl group on Met, could lead to the formation of an
α(alkylthio)alkyl radical of methionine, which can react
with paramagnetic oxygen to form a highly reactive peroxyl
H2N-Asp1-Ala
2-His6-Asp7-Ser8-Gly9-
Tyr10-Glu11-Val12-His13-His14-Gln15-Lys16-Leu17-
Val18-Phe19-Phe20-Ala21-Glu22-Asp23-Val24-Gly25-
Ser26-Asn27-Lys28-Gly29-Ala30-Ile31-Ile32-Gly33-
Leu34-Met35-Val36-Gly37-Gly38-Val39-Val40-Ile41-Ala42-COOH
Figure 2: The sequence of amyloid beta (Aβ) peptide. Methione is
present in the 35th position of Aβ(1–42).
radical or other species such as formaldehyde and sulfhydryl
[58];
4.1. In Vitro Evidences. To test the role of Met in Aβ-
mediated toxicity, the sulfur atom ofmethionine in Aβ(1–42)
was substituted by a methylene moiety (Aβ(1–42) M35NLE)
that has the same side chain length and hydrophobicity
as Met [14]. The addition of Aβ(1–42M35NLE) to 9–11-
day-old primary hippocampal cultures caused no increase
in the markers of oxidative stress and neurotoxicity [14].
Further, electron paramagnetic resonance (EPR) spin trap-
ping analyses showed that Aβ(1–42M35NLE) did not lead
to trapped free radicals, in marked contrast to native Aβ(1–
42), suggesting that that the sulfur atom of Met is key
to the Aβ(1–42)-mediated free radical formation. Three
laboratories have confirmed our results that substitution of
norleucine for Met in Aβ(1–42) significantly modulated, if
not eliminated, oxidative stress and neurotoxicity [59–61]. In
contrast, another group reported that while the 33–35 region
of Aβ(1–42) was critical for the aggregation and neurotoxic
properties of this peptide, substitution of Met by norleucine
(NL) was still toxic [47]. This different result from our
and others’ studies could be due to different experimental
conditions used in these two studies. For example, in our
study we have used aged neurons, that is, 9–11 days in culture
(by this time transporters and other key cellular components
are fully expressed); in contrast, others [47] used 2-day-old
neuronal cultures that still lack the complete expression of
the cellular proteome.
4.2. In Vivo Evidences. Most of the studies performed to
better understand the role of Met of Aβ(1–42) in oxidative
stress and neurotoxicity involved in vitro studies. However,
recently our laboratory performed the first in vivo study
of a mammalian system to address this issue [62]. The
PDAPP mouse is a transgenic mouse in which the human
APP gene having mutations corresponding to the Swedish
and Indiana familial forms of AD are expressed (APPSw, In)
behind a platelet-derived growth factor (PDGF) β-chain
promoter, resulting in Aβ accumulation, plaque formation,
and memory deficits [62]. In our study, a third mutation
in APP was introduced, namely, M631, corresponding to
Met-35 of Aβ(1–42), was substituted by leucine (M35L)
[62]. Leucine was chosen since it is a naturally occurring
amino acid with an extant codon, unlike norleucine, which
does not have a codon in the cell. Moreover, Leu, like
NLE, also exhibits similar length and hydrophobicity as Met.
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The PDAPPM631L mice showed similar levels of Aβ(1–
42) at 9 months of age, the age at which the biochemical
and pathological aspects of this study were conducted, as
the PDAPPSw, In mice. However, in contrast to the brain
of PDAPPSw, In human double mutant Tg mice, which
contained Aβ-rich plaques, the PDAPPM631L mouse brain
presented punctate deposits of Aβ(1–42), suggesting that in
addition to affecting oxidative stress, the singleMet residue of
Aβ(1–42) also is important in plaque formation. Evidence of
microglial activation was found in the PDAPPM631L mice.
Importantly, the brain of 9-month-old PDAPPM631L mice
showed no elevated oxidative stress compared to PDAPPSw, In
mice and compared to WT littermate mice, demonstrating
in vivo in mammalian brain that the Met-35 residue of
Aβ(1–42) is essential for oxidative stress associated with
this peptide. Surprisingly, this substitution did not rescue
the learning and memory deficits assessed by the Morris
water maze at 6 months of age of the PDAPPSw, In mice.
However, to determine if at a later age the deficits in learning
and memory observed in the PDAPPSw, In mice would be
modulated in the PDAPPM631Lmouse, a longitudinal study
would be required. Indeed, as noted above, while indices of
oxidative stress and pathology in brain were determined at
9 months of age, behavior necessarily had to be determined
at an earlier age, and in our study mice were tested for
behavior at 6 months of age. So, it is possible that we missed
behavioral changes that would have been manifested later.
This notion is consistent with studies of mice with other
APP mutations in which behavioral alterations observed
later in life (13 months) were not manifested earlier in
life [63]. Also, that microglial activation occurred in brain
of PDAPPM631L mice may have contributed to the lack
of rescue of behavior compared to the PDAPPSw, In mice.
Finally, Aβ(1–42) is but one neurotoxic peptide produced
from APP proteolytic processing: other, non-Aβ peptides are
produced, that is, sAPPα, Jcasp, and C31, each of which
has been implicated in neurotoxicity or other components
of the AD phenotype [64–67]. Hence, while the oxidative
stress in brain of PDAPPSw, In mice is clearly related to
Aβ(1–42), the behavioral aspects inherent in this mouse and
the PDAPPM631L mouse conceivably involve one or more
of these other APP proteolytic processing products. More
research on this topic is necessary. Our laboratory is currently
employing proteomics to explore the proteome to better
understand the role of Met-35 of Aβ(1–42) in oxidative stress
in brain in vivo.
The earliest study demonstrating in vivo the impor-
tance of methionine in Aβ(1–42)-associated oxidative stress
involved transgenic Caenorhabditis elegans (C. elegans). C.
elegans were genetically modified using an unc-54 promoter
(a muscle promoter) to express human Aβ(1–42) which
led to the deposition of Aβ(1–42) in the muscle wall of
the worm. Increased protein oxidation was found correlated
with the phenotypic expression (e.g., paralysis) of the worm
[14, 38]. Our result was recently confirmed by others [68].
If in the C. elegans that express human Aβ(1–42), Met-35
were substituted by cysteine, no oxidative stress was found,
but the deposition of modified Aβ(1–42) was not altered
[14]. One caveat to this study is that it is possible that the
ability of Cys residues to form disulfide linkages contributed
to some degree to the lack of oxidative stress inC. elegans that
expressed human Aβ(1–42)M35C.
5. Methionine and Aβ(1–42) Oligomer
A number of studies also suggest that aggregation of Aβ
peptides is essential for determining the toxicity of oxidative
stress and neurotoxicity [69, 70]. In vitro studies that
compared the toxic effect of Aβ(1–42)M35SOx and native
Aβ(1–42) showed that the when Met-35 is oxidized to the
sulfoxide in Aβ(1–42), the resulting peptide has decreased
toxicity assessed 24 h after incubation [45]. A report suggests
that oxidation of Met-35 to the sulfoxide makes this Aβ less
neurotoxic by altering production of toxic Aβ oligomers that
are reported to be the toxic species Aβ [71, 72]. However,
others showed that at long incubation times (96 h), Aβ(1–
42)M35SOx is still toxic [73]. Likely, mechanisms involved
are different than those in which shorter incubation periods
(24 h) showed no toxicity of Aβ(1–42)MSOx and may
involve aggregated extracellular peptide activating RAGE
receptors or other processes.
6. Mechanism ofMethionine-35 of Aβ(1–42)
Toxicity
The proposed Aβ-induced oxidative stress and neurotoxicity
is based on the one-electron oxidation of Met-35 to form
the sulfuranyl radical cation (Figure 3). The nature of the
oxidant is not known for certain, but two candidates
are possible among others. Molecular oxygen (zero dipole
moment; therefore, soluble in lipid bilayers), would form
superoxide radical anion as it oxidized the S atom in Met
to the sulfuranyl radical. Superoxide, in turn, could reduce
Cu2+ to Cu+ that is able to catalyze Fenton chemistry
to produce reactive and damaging hydroxyl free radicals.
Moreover, there is a report that Aβ(1–42) has Cu/Zn SOD-
like properties [74], which, if sustained by further studies,
would imply that theremust be a nearby source of superoxide
radicals needed to be scavenged to prevent further damage.
The second possible oxidant to convert Met in Aβ(1–42) to a
sulfuranyl free radical is Cu2+. Copper is shown to bind to Aβ
with a high affinity via His present at 6, 13, 14, of Aβ(1–42)
[75]. In amyloid plaques, high levels of copper were reported
and have been shown to form complex with Aβ [76]. In vitro
Aβ(1–42) and Cu(II) interaction promotes the reduction of
peptide-bound Cu2+ to Cu+ and form H2O2·Cu+, in turn,
can react with the H2O2 to form hydroxyl free radicals
[77, 78]. Moreover, it has been shown that when methionine
was added exogenously to a fragment of Aβ that lacks Met
(Aβ(1–28)), an increased rate of Cu(II) reduction occurred,
supporting the importance of methionine in Aβ-induced
toxicity [77, 79]. In vitro studies have shown that chelation
of copper by a suitable ligand inhibited the formation
of ROS. An effective chelator clioquinol (CQ, 5-chloro-7-
iodoquinolin-8-ol), hydroxyquinoline antibiotic was found
to be an effective high-affinity chelator in blocking the
formation of hydrogen peroxide by Aβ [75, 80] and resulted
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Figure 3: Methionine-35 residues in Aβ can undergo one electron oxidation to form a sulfuranyl radical, which can then initiate the process
of lipid peroxidation. For details of this proposed mechanism, please refer to the text.
in 85–90% reduction of secreted Aβ-(1–40) and Aβ-(1–
42) in Chinese hamster ovary cells overexpressing amyloid
precursor protein compared with untreated controls [81].
Further, oral administration of the clioquinol in Tg2576mice
resulted in a reduction of cortical deposition of amyloid
(49%) compared to untreated mice [82]. CQ has nanomolar
affinity for Cu2+ [83], which is sufficient to facilitate disso-
ciation of this metal ion from the low-affinity metal binding
sites of Aβ, thereby increasing levels of copper for biological
function in the brain of treated animals. Further, a small
Phase 2 clinical trial of CQ in moderately severe AD patients
for 36 weeks slowed the rate of cognitive decline, and reduced
the plasma Aβ42 levels as compared to the placebo controls
[84]. However, the role of Cu2+ remains unclear.
Since Aβ is generated by the proteolytic cleavage of
APP, which is a transmembrane protein, and Aβ has a
hydrophobic C-terminus, we proposed that Aβ peptide,
as a small oligomer, insert itself into the lipid bilayer
in an α-helical conformation. This secondary structure of
lipid-soluble Aβ(1–42) is consistent with the secondary
structure adopted by the transmembrane segments of most
bilayer-soluble proteins. NMR studies conducted on Aβ(1–
40) demonstrated that Met residue of Aβ in a micellar
environment exists in an α-helical conformation [49]. As
with all proteins with an alpha-helix conformation, the
helix portion of the protein follows the i + 4 rule, that is,
every fourth amino acid interacts. Based on the peptide
sequence of Aβ(1–42), Met-35 S-atom would interact with
carbonyl oxygen of Ile-31 [85]. In this interaction, oxygen
being more electronegative than sulfur will pull the electron
density towards it making the S-atom in Met-35 more
vulnerable to one-electron oxidation, consequently leading
to the formation of the methionine-resident sulfuranyl free
radical (MetS+·; Figure 3) [45, 58, 85]. Since this radical is
generated in the lipid bilayer, which is rich in unsaturated
fatty acid acyl chains, abstraction of allylic H atoms on
these acyl chains initiates the process of lipid peroxidation
and resulting in the formation of a carbon-centered lipid
radical (L·) [86]. The carbon-centered radical can readily
react with nonpolar and paramagnetic molecular oxygen
to form a lipid peroxyl radical (LOO·). Allylic hydrogen
atom abstraction from a neighboring lipid acyl chain results
in the formation of a lipid hydroperoxide (LOOH) and
another carbon-centered lipid radical (L·), thus propagating
the free radical chain reaction. This reaction will continue
unabated as long as there are unsaturated sites with which the
lipid acyl chain-resident L· can react. Note that the reaction
scheme in Figure 3 has the effect of amplifying the damage
caused by radical formation on Aβ(1–42). Moreover, the
lipid hydroperoxide formed in this reaction scheme can be
decomposed to reactive lipid peroxidation products such as
4-hydroxy-2-nonenal (HNE), 2-propen-1-al (acrolein), and
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isoprostanes, each of which is found in AD and MCI brain
[87]. However, if a chain-breaking antioxidant like vitamin
E is present, the chain reaction will be halted and reactive
and damaging lipid peroxidation products will no longer be
made. This is likely the mode by which vitamin E is able to
block ROS formation and neurotoxicity in neuronal systems
[33].
Referring to Figure 3, when the allylic H-atom is
abstracted by the sulfuranyl free radical, an acid of pKa-5 is
formed. This acid can react with any base, for example, water,
to lose the H+ to form reduced Met again. That is, the whole
reaction is catalytic. This model of Aβ(1–42)-induced lipid
peroxidation and subsequent oxidative damage to proteins
is consistent with the results of theoretical and experimental
studies which showed that the α-helical secondary structure
of the peptide provides stabilization of the sulfuranyl radical
formed by a one-electron oxidation of methionine. Further,
in vitro studies showed that substitution of Ile-31, that
interacts with the sulfur atom of Met-35 by the i+4 rule
of a-helices, by proline, an alpha-helix breaker, abrogates
the oxidative stress and neurotoxicity associated with Aβ(1–
42) [85]. That is, the secondary structure of Aβ(1–42)
contributes to reactivity of the neurotoxic peptide.
That lipid peroxidation requires the radical source to
be within a van der Waals distance from the allylic H-
atoms with which they react, that lipid peroxidation is well
documented in AD and MCI [11, 88], and that Aβ(1–42)
directly leads to lipid peroxidation [24], indicates that the
radical source to initiate the free radical must be soluble in
the bilayer, since free radicals are too reactive to be formed
outside the bilayer and diffuse into the bilayer to abstract an
allylic H-atom. That is, oligomeric Aβ(1–42) must be soluble
within the bilayer to initiate lipid peroxidation. Another
sequelae of lipid soluble Aβ(1–42) that adopts an α-helix
secondary structure conceivably may be related to the greater
neurotoxicity of Aβ(1–42) compared to Aβ(1–40), namely,
all α-helices have an intrinsic dipole moment, which has the
effect of stabilizing a radical intermediate, that is, sulfuranyl
free radical. Since Aβ(1–42) has two additional amino acids
in length than Aβ(1–40), the dipole moment of the former
is larger than the latter, and this increased dipole moment
conceivable could stabilize the sulfuranyl free radical onMet-
35 longer, thereby providing greater opportunity for allylic
H-atom abstraction to occur, that is, for lipid peroxidation
to be initiated.
Another study showed that substitution of Met35 to
Val leads to enhanced toxicity and cellular binding of
amyloid peptide [89]. In this study, the authors suggested
that substitution of M35 by Val might lead to a change
in the conformation of Aβ, that is, change the structure
from alpha-helix to a mixture of alpha-helical and beta-
sheet conformations, and thereby increasing the binding of
Cu+2 to this peptide and making it more toxic [89]. Studies
from our laboratory conducted by substituting His 6, 13,
14 in Aβ(1–42) by Tyr, which binds Cu2+ at least 100-
fold less well than does His, showed that this peptide still
retains its ability to induce oxidative stress and neurotoxicity
emphasizing the importance of Met-35 in the Aβ-induced
toxicity and oxidative stress [42, 45]. Also, theoretical studies
suggested that Met-mediated reduction of Cu2+ found on
His residues 6, 13, 14 of Aβ(1–42) would be facilitated by
the aromatic pi orbitals of Phe20 [90]. To test this notion,
our laboratory substituted aromatic Phe by aliphatic alanine
(Ala) and showed that while there was a slight reduction in
the oxidative stress and neurotoxicity associated with Aβ(1–
42), basically this peptide had quite similar properties as
native Aβ(1–42) [42].
A computational study from Brunelle et al. reported
that the sulfuranyl free radical on Met of one molecule of
Aβ(1–42) could abstract an H-atom from the α-carbon of
Gly-33 of an adjacent peptide in a β-sheet conformation.
The His-mechanism suggests that the H-atom abstraction
would lead to generation of C-centered free radicals which
should be able to interact with molecular oxygen leading
to the formation of a peroxyl radical and consequently to
the protein and other biomolecules damage. Basically this
mechanism suggests that no redox metals are necessary to
trigger the oxidative stress process [91]. To test this idea, we
substituted Gly-33 in Aβ(1–42) by Val (Aβ(1–42G33V)), to
prevent the H-atom transfer to Met-35 and observed that
this substitution leads to reduced levels of oxidative stress
markers and does not cause cell death [92].
7. Methionine-35 of Aβ(1–42) Localization in
Membrane is Key to Oxidative Stress
Noting that lipid peroxidation by Aβ(1–42) oligomers is
critical in our model of Aβ-induced oxidative stress and
neurotoxicity, we tested the soundness of this hypothesis. By
substitution of negatively charged aspartic acid for glycine
residue 37, which is predicted to remove the Met35 residue
out of the hydrophobic lipid bilayer, we hypothesized that
the sulfuranyl free radical would no longer be resident in
the bilayer, and that oxidative stress and neurotoxicity in
cells would be prevented [85]. This study supported our
hypothesis, and is a direct test of our model (Figure 3),
in which lipid solubility of Aβ(1–42) as small oligomers is
essential for subsequent oxidative stress and neurotoxicity
[7, 87, 93, 94]. Therefore, providing evidence that lipid
peroxidation is the initial event in the Aβ-induced toxicity, as
demonstrated by us and others [7, 93, 94], would be a major
advance in understanding potential roles of this neurotoxic
peptide.
In contrast to the previous studies on M35Nle and
M35Val substitutions studies discussed above, a recent study
suggested that while M35 is important for Aβ assembly,
this residue was not important for Aβ-induced toxicity [95].
However, there are a number of differences in the meth-
odologies of this study and those normally employed, one
of which is use of a thin film of peptide onto which buffer
is added. Oligomerization and deposition of Aβ(1–42) show
some dependence on Met-35 of this toxic peptide [62].
Consequently, in addition to the role of Met-35 described in
the review, differences in aggregation, location (i.e., mem-
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brane bilayer), and role of H-transfer from Gly-33 could play
roles in the oxidative stress observed in AD brain. Taken
together, most laboratories that have examined the issue
have provided evidence for the involvement of Aβ(1–42) in
AD oxidative stress (reviewed in [11, 23, 88] and indicated
that Met-35-associated formation of free radicals is critical
to Aβ(1–42)-induced oxidative stress and neurotoxicity
[46, 59–61]. Consistent with this notion, we suggest that
either augmenting brain-accessible exogenous antioxidants
or upregulating endogenous antioxidants may be promising
therapeutic strategies to prevent or delay this devastating
disorder. More research is needed to delineate the exact
mechanism of Aβ-induced toxicity, and our laboratory is
using redox proteomics approaches to identify oxidatively
modified proteins and altered pathways involved in brain as
a result of Aβ(1–42)-associated, Met-35-mediated oxidative
stress that may play a role in pathogenesis and progression of
AD.
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